A Randomized Double-blind Control Clinical Study on Moxifloxacin for Treatment of Bacterial Skin Infections

王爱平,余进,吴艳,丁颖果,王丹,朱学骏
DOI: https://doi.org/10.3969/j.issn.1001-6821.2003.04.001
2003-01-01
Abstract:OBJECTIVE: To evaluate the efficacy and safety of moxifloxacin in comparison with the levofloxacin in the treatment of patients with acute uncomplicated bacterial skin infections( including cellulitis, erysipelas, impetigo, furuncles, simple abscesses, wound infection).METHODS: A randomized, double-blind, parallel study was conducted. Treatment will be given for 7 to 14 days. The primary efficacy variable will be the clinical response 1 day and 7 days after end of treatment. RESULTS: Eighty-eight subjects were included, 44 subjects in the trial group (moxifloxacin) and 44 in the control group(levofloxacin). The clinical efficacy rates in the trial group at 1 day after end of treatment was 84.6%(33/39), the bacterial clearance rate was 93.8%(30/32), while in the control group were 85.0%(34/40) and 93.9%(31/33),respectively. The clinical efficacy rates in the trial group at 7 days after end of treatment was 85.3%(29/34). The bacterial clearance rate was 92.9%(26/ 28), while in the control group were 90.0%(36/40) and 93.9%(31/33),respectively. The adverse reaction rate in the trial group was 27.3%( 12/44), while in the control group was 11.4%(5/44). The difference between the two groups were no statistically significant. CONCLUSION: It suggested that moxifloxacin is an effective and safe drug for acute uncomplicated bacterial skin infections.
What problem does this paper attempt to address?